Jazz Pharmaceuticals PLC (JAZZ : NASDAQ)
Common Stock
$236.04
USD
+0.37 (0.16%)
Last updated: 2026-10-05
Follow JAZZ
JAZZ
Jazz Pharmaceuticals PLC
WealthAwesomePerformance
1 Day
+0.16%
1 Week
-0.94%
1 Month
-4.36%
YTD
+36.32%
Key Statistics
Market Cap
$15.32B
52W High
$266.38
52W Low
$128.80
P/E Ratio
16.14
50 Day MA
$247.21
200 Day MA
$211.91
Beta
0.37
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/5/2026 | $235.51 | $238.87 | $234.12 | $236.04 | $236.04 | 844,576 |
| 10/2/2026 | $233.40 | $237.77 | $231.70 | $235.67 | $235.67 | 636,600 |
| 10/1/2026 | $230.33 | $234.47 | $229.85 | $233.01 | $233.01 | 740,600 |
| 9/30/2026 | $231.60 | $236.00 | $230.39 | $231.52 | $231.52 | 1,001,900 |
| 9/29/2026 | $236.30 | $238.00 | $229.16 | $232.35 | $232.35 | 777,200 |
| 9/28/2026 | $235.67 | $238.83 | $234.63 | $238.28 | $238.28 | 788,300 |
| 9/25/2026 | $239.12 | $239.12 | $235.66 | $237.95 | $237.95 | 1,129,600 |
| 9/24/2026 | $235.82 | $236.52 | $232.00 | $236.28 | $236.28 | 551,300 |
| 9/23/2026 | $239.26 | $241.33 | $231.59 | $234.88 | $234.88 | 792,200 |
| 9/22/2026 | $242.01 | $243.21 | $239.78 | $240.57 | $240.57 | 482,000 |
Analyst Price Targets
Based on 22 analysts covering JAZZ · as of Oct 5, 2026
Wall Street analysts forecast JAZZ stock price to rise 24.7% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
US$294.27
+24.7% Upside
Current Price
US$236.04
Last close
Analyst Breakdown (22 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on JAZZ's historical volatility
30-Day Vol
26.3%
Annualized
90-Day Vol
27.6%
Annualized
Trend (90d)
-13.6%
Annualized drift
90d Mean
US$224.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$232.24 | US$212.09 – US$254.32 |
| 60 trading days | US$228.51 | US$200.97 – US$259.81 |
| 90 trading days | US$224.83 | US$192.12 – US$263.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Financials
- Revenue (TTM)
- $4.60B
- EBITDA
- $1.93B
- Profit Margin
- 20.45%
- ROE (TTM)
- 22.11%
- EPS (Diluted)
- 14.62
- Book Value
- 74.10
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About JAZZ.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GUTS | Fractyl Health, Inc. Common Stock | $4.56 | +1020.39% |
| CMND | Clearmind Medicine Inc. Common Shares | $6.00 | +739.16% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.24 | +74.48% |
| VEEA | Veea Inc. | $5.72 | +71.77% |
| PDSB | PDS Biotechnology Corp | $1.20 | +60.21% |
| BEAT | Heartbeam Inc | $0.65 | +50.39% |
| RITRF | Reitar Logtech Holdings Limited | $0.01 | +42.86% |
| QTEX | QTREX Quantum Ltd. | $1.54 | +40.00% |
JAZZ.US news timeline
2 articles covering JAZZ.US, most recent first
Latest